A population PK study into teicoplanin in intensive care and haematology patients * a strategy towards model informed precision dosing (PLATO)

Completed

• Conditions: Bacteriele infectie; 10004018

• Registration Number: NL-OMON49412
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-10-19
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

1. The patient is admitted to the ICU of the haematology department
2. The patient is at least 18 years of age on the day of inclusion
3. Is treated with teicoplanin as a part of standard care
4. Is able and willing to sign the Informed Consent form

Exclusion Criteria

1. Has previously participated in this study
2. Patient receives any form of RRT other than continuous venovenous
hemofiltration (CVVH).

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To develop a population pharmacokinetic model of teicoplanin in Intensive Care<br /><br>and Haematology patients</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- To estimate the influence of renal function on the teicoplanin clearance<br /><br>using different renal biomarkers.<br /><br><br /><br>- To investigate the impact of serum albumin on bound and unbound teicoplanin<br /><br>concentrations.<br /><br><br /><br>- To develop a limited sampling strategy for estimating the area under the<br /><br>concentration time curve of teicoplanin.</p><br>